NCT Number: NCT07803432
This study aims to establish induced pluripotent stem cell (iPSC) lines from the blood of one pediatric patient with Hutchinson-Gilford Progeria Syndrome (HGPS), a rare disease that causes rapid, premature aging, in order to build a laboratory model of the disease. The main purpose of this study is to collect a blood sample (a total of 9cc, drawn once) from the patient, reprogram the patient's blood cells into stem cells, and then differentiate these stem cells into disease-relevant cell types (such as fibroblasts, vascular smooth muscle cells, and neurons) to study how HGPS affects cells at a molecular level. These patient-derived cells will then be used entirely in the laboratory (in-vitro) to test the safety and effectiveness of candidate treatments, including an RNA-targeting gene therapy, before any such therapy would be considered for use in patients.
Trial opening soon.
Get NotifiedAll sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinically diagnosed with Hutchinson-Gilford Progeria Syndrome (HGPS) Currently followed as an outpatient at the study institution 19 years of age or younger at enrollment Able to provide written informed consent (or legal guardian able to provide consent on the patient's behalf) Willing and able to undergo a single peripheral blood draw for PBMC collection
Exclusion criteria
Clinical condition precluding safe blood collection (e.g., severe anemia, active infection at the collection site, or a bleeding disorder) Patient or legal guardian unable or unwilling to provide informed consent Collected PBMCs yield insufficient quantity or viability for successful iPSC reprogramming (results in post-hoc exclusion from cell-based analysis only, not from study consent)
Time frame: Through study completion, an estimated 12 months from PBMC collection
Established an induced pluripotent stem cell (iPSC) cell line using peripheral blood mononuclear cells (PBMCs) obtained from patients with Hutchinson-Gilford Progeria Syndrome.
Contact information is provided by the study sponsor or research team.
Bundang CHA Hospital
Other
A Case Study on the Establishment of Induced Pluripotent Stem Cell (iPSC) Lines From Hutchinson-Gilford Progeria Syndrome Patients and the In-Vitro Evaluation of Candidate Therapeutics
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06775041
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Boston, Massachusetts, United States
View Trial DetailsNCT04512963
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders
Glendale, California, United States
View Trial DetailsNCT03871972
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT00731016
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Marseille, France
View Trial Details